Novartis 4Q Revenues: $12.9 billion (+5%) 4Q Earnings: $2.0 billion (+111%) FY Revenues: $49.1 billion (+1%) FY Earnings: $7.7 billion (+15%) Comments: Innovative medicines sales were $8.8 billion in the quarter, up 6%. Growth in the quarter was driven by Cosentyx (up 57% to $615 million) and Entresto (up 172% to $185 million), partly offset by the negative impact of generic competition and pricing. Gleevec/Glivec sales were down 41% to $448 million impacted by generic competition. Tasigna ...